In this Issue:
Antidiabetics and HF, CV disease and all-cause mortality risks
Clinical and adverse outcomes with glucose-lowering drugs in type 2 diabetes
Adding liraglutide to high-dose insulin in type 2 diabetes
20-year fitness trends and prediabetes/diabetes incidence
Glucagon receptor antagonist for type 2 diabetes mellitus
Type 1 diabetes mortality in DCCT/ EDIC vs. general population
Empagliflozin’s effects on micro- and macroalbuminuria
CGM and HbA1c for evaluating glucose metabolism in children at risk for type 1 diabetes
Two studies of delayed-release metformin
NAFLD increases ventricular arrhythmias in type 2 diabetes
Please login below to download this issue (PDF)